AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MEDICAL
Beckham Coulter cautious on Q1
The lab equipment maker made 90 cents a share ex items in Q4, flat with views and matching a year ago, on a 7% rise in sales. Beckham also narrowed its Q1 forecast to 48-52 cents a share. Views were for 51 cents a share. Shares fell 1%.
Lexapro patients may pay more
Health insurers Wellpoint, Humana and Health Net are considering making it more expensive for patients to buy Forest Lab's anti-depressant Lexapro once generic versions of predecessor drug Celexa are out in '04. The HMOs say there's no big difference in the 2 drugs; Forest disagrees. Lexapro had $314 mil in sales in Forest's most recent quarter. Forest fell 1%.
Eyetech soars on 1st trading day
The biotech, which makes Macugen, a drug to curb age-related blindness, closed its first day of trading at 32.40, a 54% rise over its IPO price of $21. Macugen, which is being co-developed with Pfizer, is in phase three testing and is estimated to garner $1 bil sales upon FDA approval.